6.
Wallis R, Broder M, Wong J, Lee A, Hoq L
. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis. 2005; 41 Suppl 3:S194-8.
DOI: 10.1086/429996.
View
7.
Schiff M, Burmester G, Kent J, Pangan A, Kupper H, Fitzpatrick S
. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006; 65(7):889-94.
PMC: 1798196.
DOI: 10.1136/ard.2005.043166.
View
8.
Garg A, Wadhera R, Gulati S, Kalrat R, Singh S
. Tongue histoplasmosis mimicking malignancy. J Assoc Physicians India. 2012; 59:591-2.
View
9.
Galandiuk S, Davis B
. Infliximab-induced disseminated histoplasmosis in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol. 2008; 5(5):283-7.
DOI: 10.1038/ncpgasthep1119.
View
10.
Deepe Jr G
. Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clin Infect Dis. 2005; 41 Suppl 3:S204-7.
DOI: 10.1086/429999.
View
11.
Azar M, Loyd J, Relich R, Wheat L, Hage C
. Current Concepts in the Epidemiology, Diagnosis, and Management of Histoplasmosis Syndromes. Semin Respir Crit Care Med. 2020; 41(1):13-30.
DOI: 10.1055/s-0039-1698429.
View
12.
Armstrong P, Jackson B, Haselow D, Fields V, Ireland M, Austin C
. Multistate Epidemiology of Histoplasmosis, United States, 2011-2014. Emerg Infect Dis. 2018; 24(3):425-431.
PMC: 5823339.
DOI: 10.3201/eid2403.171258.
View
13.
Park S, Cheong J, Kyi K, Aranez J, Abu-Farsakh S, Whitney-Miller C
. Cholestasis and disseminated histoplasmosis in a psoriatic patient on infliximab: case report and review of literature. BMC Gastroenterol. 2020; 20(1):141.
PMC: 7206703.
DOI: 10.1186/s12876-020-01290-3.
View
14.
Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A
. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008; 58(5):1248-57.
DOI: 10.1002/art.23447.
View
15.
Dogenski L, Pasqualotto E, Dutra M, Rovani G, Trentin M, De Carli J
. Uncommon case of histoplasmosis with oral manifestation: A case report of diagnosis in a South American patient. Int J Surg Case Rep. 2022; 93:106920.
PMC: 8918853.
DOI: 10.1016/j.ijscr.2022.106920.
View
16.
Minhas S, Sajjad A, Kashif M, Taj F, Waddani H, Khurshid Z
. Oral Ulcers Presentation in Systemic Diseases: An Update. Open Access Maced J Med Sci. 2020; 7(19):3341-3347.
PMC: 6953949.
DOI: 10.3889/oamjms.2019.689.
View
17.
Porter S, Leao J
. Review article: oral ulcers and its relevance to systemic disorders. Aliment Pharmacol Ther. 2005; 21(4):295-306.
DOI: 10.1111/j.1365-2036.2005.02333.x.
View
18.
James A, Gunasekaran N, Thayalan D, Krishnan R, Mahalingam R
. Diagnosing oral lesions in immunocompromised individuals: A case report with a review of literature. J Oral Maxillofac Pathol. 2022; 26(Suppl 1):S139-S142.
PMC: 9017828.
DOI: 10.4103/jomfp.jomfp_281_21.
View
19.
Gutierrez M, Canton A, Sosa N, Puga E, Talavera L
. Disseminated histoplasmosis in patients with AIDS in Panama: a review of 104 cases. Clin Infect Dis. 2005; 40(8):1199-202.
DOI: 10.1086/428842.
View
20.
van Welzen B, van Erpecum K, Haas P, Ten Kate F, Mudrikova T
. Severe cholestasis due to disseminated histoplasmosis under adalimumab-containing immunosuppressive therapy. Clin Res Hepatol Gastroenterol. 2013; 37(4):e105-7.
DOI: 10.1016/j.clinre.2013.03.008.
View